Adverse events(during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events: other · Adults (general population)
1 finding from 1 review
Adverse events: death · people requiring admission to hospital
It is very uncertain whether hospital‐in‐the‐home changes adverse events: death compared with hospital admission (very low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events1 · people following primary uncemented THA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events · People with P. vivax malaria1
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events (during intervention) · children/adolescents with post‐traumatic stress and related depressive/anxiety symptoms
1 finding from 1 review
Serious adverse events (3 to 4 weeks · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Serious adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review